American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary
DAIC
FEBRUARY 29, 2024
12:15 p.m.
Diabetes Innovation Preserved Ejection Fraction 
103 
Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research
DAIC
MARCH 25, 2025
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
What Cardiometabolic Clinicians Can Be Thankful For This Year
Cardiometabolic Health Congress
NOVEMBER 22, 2024
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Eversense’s 365-day CGM and Medtronic’s Simplera Sync were among the major highlights, offering patients with diabetes more comfortable, longer-lasting monitoring options.
Heartfelt innovations: advances in cardiorenal care
The British Journal of Cardiology
JANUARY 14, 2025
We report from the 19 th Annual Scientific Meeting of the Cardiorenal Forum held in London on 4 th October 2024, which served as a dynamic platform for experts in cardiology, diabetes, and renal medicine to converge and exchange the latest insights on managing heart and kidney failure.
5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC)
Cardiometabolic Health Congress
NOVEMBER 14, 2024
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,
Let's personalize your content